Positive Phase III data for omecamtiv mecarbil in patients with heart failure with reduced ejection fraction

In GALACTIC-HF (n=8,256), omecamtiv mecarbil (maintenance dose guided by plasma levels) reduced the risk of a composite primary endpoint compared to placebo (time to CV death or first heart failure event; HR 0.92; 95% CI 0.86-0.99, p=0.0252).

Source:

Biospace Inc.